1 Mapping suitability for Buruli ulcer at fine spatial scales across

2 Africa: a modelling study

- 3 Hope Simpson MSc¹*, Earnest Njih Tabah PhD², Richard Phillips MD³, Michael Frimpong PhD³, Issaka
- 4 Maman PhD⁴, Joseph Timothy PhD¹, Paul Saunderson MD⁵, Rachel L Pullan PhD¹, Jorge Cano PhD¹
- 5 *corresponding author: hope.simpson@lshtm.ac.uk

6 Author Affiliations

- 7 ¹London School of Hygiene and Tropical Medicine, United Kingdom
- 8 ² National Yaws, Leishmaniasis, Leprosy and Buruli ulcer Control Programme, Cameroon
- 9 ³School of Medical Sciences, Kwame Nkrumah University of Science and Technology, Ghana
- ⁴ National Reference Laboratory for Buruli Ulcer Disease in Togo; Ecole Supérieure des Techniques
- 11 Biologiques et Alimentaires (ESTBA), Laboratoire des Sciences Biologiques et des Substances
- 12 Bioactives, Université de Lomé, Lomé, Togo
- 13 ⁵Accelerating Integrated Management (AIM) Initiative, Accra, Ghana.

15 Abstract

16 Background

17 Buruli ulcer (BU) is a disabling and stigmatising neglected tropical disease (NTD). Its distribution and 18 burden are unknown because of underdiagnosis and underreporting. It is caused by Mycobacterium 19 ulcerans, an environmental pathogen whose environmental niche and transmission routes are not 20 fully understood. Active BU case searches can limit morbidity by identifying cases and linking them 21 to treatment, but these are mostly restricted to well-known endemic areas. A better understanding 22 of environmental suitability for environmental reservoirs of *M. ulcerans* and BU disease would 23 advance understanding of the disease's ecology and burden, and could inform targeted surveillance. 24 Methodology/Principal Findings 25 We used previously compiled point-level datasets of BU and *M. ulcerans* occurrence, evidence for 26 BU occurrence within national and sub-national areas, and diverse environmental datasets. We 27 fitted relationships between BU and *M. ulcerans* occurrence and environmental predictors by

applying regression and machine learning based algorithms, combined in an ensemble model to

29 characterise the optimal ecological niche for the disease and bacterium across Africa at a resolution

30 of 5km x 5km. Climate and atmospheric variables were the strongest predictors of both

31 distributions, while indicators of human disturbance including damming and deforestation, drove

32 local variation in suitability. We identified patchy foci of suitability throughout West and Central

33 Africa, including areas with no previous evidence of the disease. Predicted suitability for *M. ulcerans*

34 was wider but overlapping with that of BU. The estimated population living in areas predicted

suitable for the bacterium and disease was 29.1 million.

36 Conclusions/Significance

37 These maps could be used to inform burden estimations and case searches which would generate a

38 more complete understanding of the spatial distribution of BU in Africa, and may guide control

39 programmes to identify cases beyond the well-known endemic areas.

40

41

43 Author summary

Like many neglected tropical diseases primarily affecting the rural poor, Buruli ulcer (BU) is under-44 45 detected and under-reported within routine health information systems. As such, the burden and 46 distribution are not fully known, impeding appropriate targeting of health resources, control, and 47 care for people affected. Having previously evaluated and mapped the existing evidence for BU and 48 its causative agent *M. ulcerans*, we concluded that the disease was likely to occur beyond the range 49 of known endemic areas. However, we were left with the question of where exactly these 50 undetected cases might be occurring. Answering this question required a more fine-scale approach: 51 BU is highly focal, presumably due to local variation in the environmental factors which determine 52 suitability for *M. ulcerans* survival and transmission to humans. We used the compiled evidence and 53 geographical datasets to build statistical models representing the relationship between 54 environmental factors and previously reported cases. This allowed us to define the ecological niche 55 of BU, and subsequently to identify areas across Africa where this niche was met, providing suitable 56 conditions for the disease. We constructed separate models of suitability for *M. ulcerans*, using 57 locations where its DNA had been detected in environmental sources. Unsurprisingly, suitability for 58 *M. ulcerans* was predicted to be wider than, but geographically overlapping with that for BU. This 59 implies that beyond the conditions necessary for survival of the bacterium, additional factors are 60 required for transmission to humans. The high-resolution suitability maps we present are intended to guide case search activities which may identify endemic areas beyond the known endemic range. 61 62 Data on the true prevalence of BU from targeted case searches within predicted-suitable areas will 63 also allow us to validate and refine the models, and potentially predict the actual probability of cases 64 occurring within predicted suitable areas.

65

67 Introduction

68 Buruli ulcer (BU) is a chronic necrotizing disease of the skin and soft tissue, which causes debilitating 69 symptoms and sequelae, associated with a high burden of morbidity and stigma for patients and 70 economic costs for affected households [1-3]. These impacts are felt particularly strongly in 71 impoverished rural communities with poor access to health services [3, 4]. The infectious agent is 72 Mycobacterium ulcerans, a slow-growing environmental bacterium which may be transmitted from 73 aquatic environments to humans via inhalation or ingestion, or by penetration of the skin [1, 5, 6]. 74 The main control strategy is active case finding in endemic areas to promote early case detection 75 and effective treatment, which limits disease progression [7, 8]. BU occurs mostly in tropical and 76 subtropical areas of West and Central Africa, with smaller foci in parts of Asia, South America, the 77 Western Pacific and Australasia [9]. However, the disease is recognised to be underdiagnosed and 78 under-reported, and may occur undetected in other parts of the world [9-12]. 79 The distribution of BU is presumably linked to environmental suitability for *M. ulcerans* survival and 80 replication, as well as to human and environmental factors favouring transmission [13]. On a 81 continental scale, BU appears to be limited by climatic factors: it is restricted to tropical and 82 subtropical regions and absent from arid areas [14]. Within endemic areas, the disease shows a 83 highly focal distribution [15-17], but reasons for this are not well understood, since the precise niche 84 and transmission routes of *M. ulcerans* have been difficult to characterise [18]. The pathogen has 85 only been cultured from environmental and animal samples a handful of times [19-21], although it 86 has been detected by PCR in aquatic environments of endemic and non-endemic areas, and a in 87 wide range of potential hosts including mammals, fish, amphibians, and aquatic and terrestrial 88 insects [22-26]. Consistent with the ecology of an environmental pathogen, the distribution of M. 89 ulcerans in the environment appears to be wider than that of BU, suggesting that factors beyond 90 environmental suitability for *M. ulcerans* are required for transmission [13, 14, 27]. 91 Our understanding of the pathways of BU infection is also limited, partly by its long and variable 92 incubation period, which makes it difficult for patients and clinicians to attribute particular events or 93 activities to disease acquisition [28]. Local spatial analysis has identified several environmental 94 variables associated with increased BU incidence, primarily proximity to rivers, as well as 95 environmental disturbance and land-use changes including deforestation, urbanisation, 96 agriculturalization and mining [17, 29]. Case control studies have identified contact with unprotected 97 waterbodies as a risk factor for disease [30], suggesting that activities which bring people into 98 contact with water sources harbouring *M. ulcerans* increase the risk of disease acquisition [31-33].

- 99 Given the recognised scale of BU under-detection and under-reporting, it is likely that BU occurs
- 100 beyond the known range of reported cases. A better understanding of potential suitability for the
- 101 pathogen in the environment and the disease in humans would help to improve its surveillance and
- 102 control in countries where is known to be endemic. Furthermore, characterisation of the
- 103 environmental factors linked to suitability for *M. ulcerans* and BU may reveal areas at risk for disease
- 104 emergence, or places harbouring unrecognised cases.
- 105 In this investigation, we aim to identify environmental factors which characterise the environmental
- 106 niche of *M. ulcerans* and BU disease in humans, and to model their respective relationships with BU.
- 107 These analyses will be used to identify areas of continental Africa which may be suitable for *M*.
- 108 *ulcerans* or BU based on their environmental characteristics.

109 Methods

110 Data on Buruli ulcer and *M. ulcerans* distribution

- 111 We used previously compiled spatial datasets of point locations of recorded occurrences of BU
- disease in humans, and of detection of *M. ulcerans* genetic material in biotic and abiotic
- environmental samples [9, 34]. Data for the final models was extracted from the database on
- 114 03/01/2020.
- BU occurrence locations were restricted to those where BU infection was confirmed by a positive
- result for PCR targeting IS2404, or histopathology consistent with BU disease. To explore the model's
- sensitivity to the case definition, we repeated the analysis using all locations where clinically
- diagnosed BU had been reported. We hereon refer to the two datasets as 'confirmed occurrences'
- 119 and 'all occurrences' respectively.
- 120 The environmental dataset was restricted to locations where *M. ulcerans* DNA had been identified
- and distinguished from that of other mycobacteria: either by multiplex qPCR assays quantifying the
- relative copy numbers of IS2404, IS2606 and the KR-B domain [35]; byvariable nucleotide tandem
- 123 repeat (VNTR); or mycobacterial interspersed repetitive unit (MIRU) typing [36, 37]. We hereon refer
- 124 to this dataset as 'environmental occurrences'.
- 125 All records were restricted to locations with reliable geographical coordinates and deduplicated by
- 126 geographical location. Human and environmental locations were weighted by the year and the
- 127 specificity of confirmatory tests reported (S1 Text).
- 128 Environmental datasets used in ecological modelling
- 129 We assembled gridded datasets of 51 environmental variables considered relevant to the ecological
- 130 niche of *M. ulcerans* [18]. All variables and their sources are shown in Table 1 and full details are
- 131 provided in S3 Text.
- 132

133 Variable selection

- 134 We compiled the gridded predictor variables at a resolution of 5km x 5km within a rectangular area
- 135 of West Africa from latitude -13.57195, longitude -4.11032, to lat. 16.67107, long. 14.493. This area
- 136 contained 94% of all BU occurrence locations, 95% of confirmed BU occurrence locations, and all
- 137 environmental occurrence locations. We extracted the values of predictor variables at the locations
- 138 of BU cases (all occurrences) and environmental occurrences of *M. ulcerans* DNA.
- 139 We used principal components analysis (PCA) to identify the minimum set of variables that best
- 140 characterized the environment at observations of BU and of *M. ulcerans* from the global
- 141 environment. We undertook separate PCAs on the human (confirmed cases) and environmental
- datasets, selecting variables that contributed most strongly to the minimum number of principal
- 143 components collectively accounting for at least 80% of the total dataset variance.

144 Pseudoabsence and Background data

145 The occurrence data used in the modelling framework were supplemented with systematically

- 146 generated pseudo-absence and background data. The use of artificial absence data is a common
- 147 approach in species distribution modelling, designed to account for geographically biased presence
- 148 data and sparse absence data [38]. The terms background and pseudoabsence are often used
- interchangeably to describe artificial absence data, though Elith and Hijmans distinguish them on the
- basis that background data are intended to characterise the 'environmental domain' of the study-
- 151 helping to account for geographical bias, while pseudoabsence data represent areas assumed to be
- unsuitable for the species and are intended to capture the environment in these areas [39]. We
- 153 hereon use the terms in this sense.
- 154 Pseudoabsence and background points were both selected from a restricted geographical extent
- around occurrence points, defined by the spatial structure of the occurrence predictors. This has
- been recommended by previous authors as way to provide an ecologically meaningful definition of
- 157 the study range [40]. Pseudoabsence points were sampled at higher density in areas of weaker
- evidence according to a systematic review of the geographical distribution of BU [41]. Background
- points were sampled at higher density around recorded occurrence points. More details on the
- 160 generation of pseudoabsence and background points are provided in S2 Text.
- 161 Pseudoabsence and background weights were uniform within datasets and assigned so their sum
- 162 was equal to the sum of occurrence weights in each model [42]. Human background points were
- 163 restricted to a minimum distance of 10km from any occurrence location, and environmental
- 164 background points were restricted to 10km from any human or environmental occurrence location.

165 The distribution of BU and *M. ulcerans* occurrences, pseudoabsence and background points are 166 shown in S1 Figure and S2 Figure.

167 Ensemble modelling

- 168 The environmental factors selected through PCA were used as predictor variables. We used the
- 169 biomod2 package in R [43, 44] to implement seven algorithms: generalized linear models (GLM),
- 170 generalized additive models (GAM), generalized boosted regression models (GBM), artificial neural
- 171 networks (ANN), multiple adaptive regression splines (MARS), maximum entropy (MaxEnt) and
- 172 random forest (RF).
- 173 Individual model algorithms were each run 20 times with a random sample of 80% of data points,
- and evaluated with the remaining 20%. For each algorithm we calculated the mean true skill statistic
- 175 (TSS), the mean positive correctly classified (PCC) and the mean area under the curve (AUC) of the
- 176 receiver operation characteristic (ROC) [45]. Models with mean AUC above 0.8 were integrated in an
- 177 ensemble using committee averaging to attribute higher weight to better performing models.
- 178 We plotted the importance values representing each variable's contribution to the model and
- 179 created marginal effect plots for the modelled covariates in the highest performing model ensemble.

180 Estimating total population living in suitable areas

- 181 We calculated the total area suitable for BU, *M. ulcerans*, and the total area suitable for both, and
- 182 extracted estimates of the population living in each of these areas from a raster representing
- 183 estimated number of people per 1km² grid square in 2020 [46].

184 **Results**

185 Datasets of BU occurrence in humans and *M. ulcerans* DNA detection in the environment

- 186 The modelled data included 2,183 unique point locations with reported cases of BU in Africa (Figure
- 187 1A). BU was confirmed by PCR or histopathology at 738 unique locations. There were 91 unique
- 188 locations where *M. ulcerans* DNA had been detected by MIRU, VNTR or qPCR (Figure 1B). The
- 189 dataset of clinically diagnosed human cases represented 16 countries, mostly in West and Central
- 190 Africa, with a few in East and southeast Africa. The confirmed cases were restricted to 13 countries.
- 191 The time period of human case detection was from 1957 to 2019. The median year of diagnosis was
- 192 2010. The 91 records of environmental detection of *M. ulcerans* represented three countries: Ghana,
- 193 Cameroon and Benin, and covered the period from 2006 to 2018 with a median year of detection of
- 194 2013.
- 195 **Figure 1A**: Selection of BU occurrence points from BU database
- 196 Figure 1B: Selection of model environmental occurrence points from global database of MU197 occurrences

198 Principal components analysis

- 199 Ten principal components (PCs) collectively contributed 86% of variation in the human BU
- 200 occurrence locations. Seven PCs characterised the environmental locations. The variables selected
- 201 for each model are shown in S3 Text. The mean contribution of the most important predictors of
- 202 human BU occurrence dropped sharply at 150km, while the contribution of the predictors of
- 203 environmental detection of *M. ulcerans* declined at 300km (S4 Text).

204 Environmental suitability for BU

- 205 All individual distribution models performed well with ROC scores above 0.8 (S5 Text). Mean PCC
- scores were between 79.3 and 91.6% and mean TSS scores were between 0.57 and 0.79 (Figures A
- and B, S5 Text).RF performed best with a mean PCC of 91.6%, a mean TSS of 0.79 and mean ROC
- 208 0.95. The final ensemble model showed an overall mean ROC of 0.96 with sensitivity of 87.1% and
- specificity of 92.9%. The mean TSS was 0.80 and the mean kappa score was 0.80 (Table 2).

		Weighted Mean	Lower Cl	Upper Cl
DII	TSS	0.797	0.797	0.794
вU suitability	ROC	0.963	0.961	0.963
suitability	kappa	0.801	0.804	0.797
N 41 L	TSS	0.885	0.885	0.896
IVIU auitability	ROC	0.96	0.96	0.961
suitability	kappa	0.894	0.894	0.894

211 Table 2: Validation metrics for ensemble models for BU and *M. ulcerans* suitability

212

213 The minimum temperature of the coldest month was the strongest contributor to the RF models, 214 followed by PET and distance to dams (Figure A in S6 Text). Environments with minimum 215 temperature below 18°C were unsuitable, but suitability increased sharply at this temperature, 216 decreased a little from 20-21°C, before increasing again, remaining high up to 24°C (Figure A in S7 217 Text). Optimal values of PET were between 1,000 and 1,500mm per month, corresponding to 218 tropical rainforest canopy cover. There was a gradual decline in suitability for BU with increasing 219 distance to the nearest dam up to a distance of 80km, after which suitability dropped rapidly. 220 The overall distribution was constrained to humid tropical areas and local scale variation appeared 221 to be driven by hydrological features and deforestation patterns (Figure 2). The total area predicted to be suitable for BU was 338,500 km², and the total population living in areas predicted suitable was 222 69.7 million (Table 3). Pockets of suitability for BU totalling >100 km² were predicted in 16 countries 223 224 in Africa, including all 12 countries along the west-central African coastline from Liberia to Angola 225 (S2 Table). Angola had the widest area predicted suitable, followed by the Democratic Republic of 226 the Congo, although the patches of suitability predicted in these countries were associated with high 227 uncertainty. Nigeria had the largest population at risk, with 17.8 million predicted to be living in 228 areas suitable for BU, followed by the Democratic Republic of the Congo where 10.8 million were 229 predicted to be living in suitable areas (S2 Table). 230 The model including all cases of BU (S3 Figure) gave similar results to the model including confirmed 231 cases only. The Pearson coefficient of correlation between the two models was 0.86. 232 Figure 2: Predicted environmental suitability for the occurrence of BU disease in humans and

associated error of prediction.

234 Environmental suitability for M. ulcerans

All models performed well with ROC above 0.8, apart from MAXENT Phillips which was excluded

- 236 from the ensemble model. Mean PCC varied from 0.80- 0.89 between models and mean TSS was
- between 0.54 and 0.77 (Figures C and D, S5 Text). RF outperformed other algorithms in predicting

the occurrence of *M. ulcerans*. The final ensemble model had a mean TSS score of 0.87, with a
sensitivity of 92.3 and specificity of 94.5% (Table 2). The ROC sore was 0.99 and the kappa score was
0.87.

241 The minimum temperature of the coldest month was the strongest predictor of *M. ulcerans*

occurrence in the RF models, accounting for 24.6% of all variance in the model (Figure B in S6 Text).

243 Distance to deforested areas was also a strong predictor, accounting for 23.7% of the variance.

244 Suitability was low at coldest month minimum temperatures below 18°C, and increased sharply to a

245 peak at 25°C. There was a strong response to the distance to deforested areas, with high suitability

at close range to deforested areas, decreasing sharply at 25km (Figure B in S6 Text).

247 The overall distribution appeared to be restricted by suitability for minimum temperature and

248 precipitation in the driest month, with local variation driven by deforestation (Figure 3). The total

area predicted to be suitable for *M. ulcerans* was 833,975km², and the total population living in

areas predicted suitable was 71.2 million (Table 3). Pockets of suitability were predicted in 31

countries (S2 Table). The DRC had the widest area predicted suitable (184,500 km²) followed by Côte

d'Ivoire (120,600 km²). The highest population living in suitable areas was in Nigeria (26.7 million).

Figure 3: Predicted environmental suitability for the occurrence of *M. ulcerans* in the environment
and associated error of prediction.

255 **Overlap of suitability for BU and** *M. ulcerans*

256 The total area predicted to be suitable for both BU and *M. ulcerans* was 126,775 km², with 29.1 257 million people predicted to be living in areas at risk. There were notable differences in the extents of 258 the areas predicted suitable for BU disease and environmental *M. ulcerans* (Figure 4). There were 259 wide areas in Sierra Leone and Cote d'Ivoire predicted suitable for *M. ulcerans* but not for BU 260 disease, which was restricted to smaller pockets within these countries. Suitability for M. ulcerans 261 was also predicted outside the predicted range of BU across central Africa and along the north-west 262 cost of Mozambique, eastern Tanzania and coastal Kenya. In contrast, there were large patches in 263 Central Africa predicted suitable for BU but not suitable for *M. ulcerans*. Ghana followed by 264 Cameroon had the widest area predicted suitable for both BU and *M. ulcerans*. The highest 265 populations living in areas predicted suitable for both BU and *M. ulcerans* were in Nigeria and 266 Ghana, with 11.4 and 8.0 million respectively at risk.

Figure 4: Predicted overlap of environmental suitability for BU and of *M. ulcerans* occurrence.

268

269 Table 3: Total area predicted suitable and population in areas at risk for Buruli ulcer, M. ulcerans,

and both, in Africa

		Total area			Population in		
		suitable (km²)	Lower bound	Upper bound	suitable areas	Lower bound	Upper bound
	BU	338 <i>,</i> 500	283,950	425,600	69,740,630	62,573,091	83,050,754
	MU	912,600	767,775	1,112,275	88,542,574	75,380,436	104,645,747
	BU & MU	126,775	94,800	177,700	29,124,902	22,597,071	39,371,153
271							

272 Suitability for BU and *M. ulcerans* is shown by country in S1 Supporting Maps.

273 **Discussion**

274	We have used ecological niche modelling to identify environmental factors associated with the
275	occurrence of Buruli ulcer and its causative agent <i>M. ulcerans</i> , and to predict environmental
276	suitability for the disease and bacterium across continental Africa. Incorporating existing data on BU
277	distribution and a geo-environmental definition of the range of occurrences, the resulting maps
278	represent evidence-based predictions within a relevant spatial context.
279	There was substantial overlap in the factors contributing to suitability for human cases and
280	environmental occurrence. Both BU and <i>M. ulcerans</i> were constrained to particular bioclimatic
281	zones by environmental predictors which varied over large areas, characterising the humid tropical
282	realm where BU is endemic in Africa. Our finding that areas with minimum temperature less than
283	18°C were unsuitable for BU supports evidence for a different epidemiology of the disease in Africa
284	compared to endemic areas of temperate Australia and Japan [47]. Local-scale variation in factors
285	including the distance to dams, deforestation and hydrology resulted in a patchy distribution of
286	predicted suitability, consistent with our understanding of the epidemiology of BU, which is
287	recognised to be highly focal in endemic settings [48].
288	We identified pockets of suitability for BU in patchy foci throughout the known-endemic range of
289	the disease, particularly in the tropical zones of countries around the Gulf of Guinea. Throughout
290	this range, suitability was predicted in regions not previously recognised as endemic. For example,
291	two foci of suitability were predicted in Equatorial Guinea, which had no evidence of cases reported
292	in peer-reviewed literature. However, these two areas correspond to the origins of a number of
293	cases diagnosed by an expert in BU between 1995 and 2005 [49, 50].
294	Some locations in northern Cameroon with previous evidence of PCR confirmed BU were found to
295	be unsuitable for the disease. This discordance may be due to the model's failure to identify suitable

- environments in areas of lower BU incidence. However, given the great volume of surveillance data
- 297 collected by the well-established BU control programme in Cameroon, some patients are likely to

298	have been diagnosed outside the region where they acquired the disease [51], and we consider it
299	plausible that some regions where BU has been recorded are not actually suitable for transmission.
300	The suitability maps provide a depiction of areas potentially at risk for BU beyond what is known
301	from the distribution of reported cases, currently the basis for targeting of surveillance and control.
302	Given the recognised scale of underreporting of BU [41], the current approach is likely to exclude
303	cases outside of known disease foci, and we suggest that areas predicted suitable for BU could be
304	considered as targets for case finding activities, with the aim of identifying unrecognised foci and
305	patients not known to the health system. Based on the wide areas of suitability predicted by this
306	work and existing evidence of under-reporting of BU [52], the south of Nigeria would be a key target
307	for case finding activities. There were wide areas predicted suitable in the Republic of Congo, the
308	DRC and Angola, although these predictions were associated with significant uncertainty, which
309	should be considered in the design of any future surveys. Suitable areas of Equatorial Guinea with
310	historical evidence of cases would also be targets for case finding, although in this case the predicted
311	suitable areas are more restricted, potentially necessitating a more stratified approach. A
312	comparable approach has been applied to target malaria elimination efforts to transmission
313	hotspots predicted through geospatial risk mapping [53], employing environmental modelling to
314	impute risk in the absence of full surveillance coverage.
315	The model predictions could also be used to inform the design of cross-sectional surveys for BU,
316	combining exhaustive case searches with environmental modelling to achieve robust estimates of
317	prevalence. In a nationwide survey for podoconiosis in Cameroon, the selection of survey
318	communities was stratified according predicted suitability for the disease based on a model trained
319	mainly using data from Ethiopia [54]. This survey identified higher rates of podoconiosis in
320	communities that were predicted suitable, implying a benefit in terms of the cost per case identified,
321	compared to a survey employing random selection of survey communities.

322 The validation metrics we calculated demonstrate the ability of the models to predict BU and M. 323 ulcerans occurrence with high accuracy. However, these measures do not indicate the models' 324 generalisability to areas beyond the range of known locations. Validation against external datasets 325 would be required to assess this guality and is a target for future analysis. 326 The scale of analysis (grid cells at 5km x 5km) may have limited our ability to quantify the effect of 327 predictors varying over small geographical scales. For example, the relatively small contribution of 328 distance to waterways on suitability for BU was a surprising result, given that proximity to and 329 contact with rivers have been identified as risk factors for BU disease [13, 18]. However, the 330 variation we were able to capture in this predictor was limited, since most of the land area in 331 tropical and sub-tropical Africa is within 10km of a river or stream, and much is within 5km. A 332 previous analysis of land use and landcover and BU presence at large spatial scales in Benin found no 333 association of BU at community level with proximity to water bodies [55]. The scale of analysis may 334 also have limited our ability to capture fine scale variation in environmental suitability for BU. Our 335 models predicted large contiguous areas of suitability in some areas with suitable bioclimatic 336 conditions and within close proximity to stable night lights and deforested areas. Such areas may be 337 suitable in reality, but exhibit an uneven distribution of disease due to factors not included in our 338 models.

We have identified areas of high suitability for BU and *M. ulcerans* within known endemic-areas, and in areas not currently recognised as endemic, but with evidence of possible undiagnosed or misdiagnosed BU. The population at highest risk of BU is within areas where BU and *M. ulcerans* niches overlap, comprising almost 30 million people in 2020. The focal nature of BU distribution, the recognised scale of under-detection, and the impact of late diagnosis on disease severity strongly suggest a targeted approach to active case finding as a means to control this disease. The fine-scale, evidence-based predictions presented here could provide a tool to target such efforts, which will

- 346 help to increase the proportion of cases linked to treatment, and contribute further research to
- 347 establish the burden and distribution of this devastating disease.

348

350 Acknowledgements

351 The AIM Initiative was the sole funder of this work. We would like to recognise the contribution of

- 352 all health workers, researchers and data managers who recorded cases of Buruli ulcer which were
- compiled into the global database of infections underpinning this study.

354 Author contributions

- 355 RP and JC acquired the funding that enabled this project. JC conceptualised the study. JC and HS
- 356 together developed the investigation and methodology- including the software (code for the
- analysis), and produced the visualisations presented. HS curated the data analysed, some of which
- 358 was originally collected by other authors: ET, RP, MF, IM and JT. HS undertook the formal analysis
- and prepared the original draft. All authors critically reviewed the draft.

360

362 Supporting Information

- **S1 Text**: Weighting of occurrence points
- 364 S2 Text: Selection of background and pseudoabsence points
- **S3 Text:** Environmental variables used in modelling
- S1 Figure: Distribution and weights of confirmed BU occurrence locations, background and
 pseudoabsence points
- 368 S2 Figure: Distribution and weights of environmental *M. ulcerans* DNA occurrence locations,
 369 background and pseudoabsence points
- **S3 Figure**: Predicted environmental suitability for the occurrence of BU disease in humans and
- associated error of prediction, including all clinically diagnosed cases of BU
- **S4 Text:** Spatial structure of occurrence predictors
- **S5 Text**: Individual model performance evaluation statistics
- **S6 Text**: Variable importance plots for random forest models
- **S7 Text**: Marginal effect plots for random forest models
- **S1 Table**: Total area predicted suitable and population living in suitable areas for Buruli ulcer, *M*.
- *ulcerans*, and both, by country in African continent.

378 <u>References</u>

 379
 1.
 Walsh DS, Portaels F, Meyers WM. Buruli ulcer (Mycobacterium ulcerans infection).

380 Transactions of the Royal Society of Tropical Medicine and Hygiene. 2008;102(10):969-78. Epub

381 2008/07/29. doi: 10.1016/j.trstmh.2008.06.006. PubMed PMID: 18657836.

Roltgen K, Pluschke G. Epidemiology and disease burden of Buruli ulcer: a review. Research
 and Reports in Tropical Medicine. 2015;6:59-73. doi: 10.2147/rrtm.s62026. PubMed PMID:
 WOS:000219035500008.

385 3. Amoakoh HB, Aikins M. Household cost of out-patient treatment of Buruli ulcer in Ghana: a

case study of Obom in Ga South Municipality. BMC health services research. 2013;13:507. Epub

387 2013/12/10. doi: 10.1186/1472-6963-13-507. PubMed PMID: 24313975; PubMed Central PMCID:

388 PMCPmc4029088.

389 4. Chukwu JN, Meka AO, Nwafor CC, Oshi DC, Madichie NO, Ekeke N, et al. Financial burden of

390 health care for Buruli ulcer patients in Nigeria: the patients' perspective. International health.

391 2017;9(1):36-43. Epub 2016/12/18. doi: 10.1093/inthealth/ihw056. PubMed PMID: 27986841.

392 5. Duker AA, Portaels F, Hale M. Pathways of Mycobacterium ulcerans infection: a review.

Environment international. 2006;32(4):567-73. Epub 2006/02/24. doi: 10.1016/j.envint.2006.01.002.
PubMed PMID: 16492390.

395 6. Rodhain F. [Buruli ulcer: hypothetical modes of transmission of Mycobacterium ulcerans].

Bulletin de l'Academie nationale de medecine. 2012;196(3):685-90; discussion 90-1. Epub

397 2013/03/12. PubMed PMID: 23472356.

398 7. Organisation WH. Buruli ulcer (Mycobacterium ulcerans infection) 2019 [27/08/2019].

Available from: <u>https://www.who.int/news-room/fact-sheets/detail/buruli-ulcer-(mycobacterium-</u>
 <u>ulcerans-infection</u>).

401 8. Phillips RO, Robert J, Abass KM, Thompson W, Sarfo FS, Wilson T, et al. Rifampicin and
402 clarithromycin (extended release) versus rifampicin and streptomycin for limited Buruli ulcer lesions:

a randomised, open-label, non-inferiority phase 3 trial. The Lancet. 2020.

Simpson H, Deribe K, Tabah EN, Peters A, Maman I, Frimpong M, et al. Mapping the global
distribution of Buruli ulcer: a systematic review with evidence consensus. Lancet Glob Health.

406 2019;7(7):e912-e22. Epub 2019/06/16. doi: 10.1016/S2214-109X(19)30171-8. PubMed PMID:

407 31200890; PubMed Central PMCID: PMCPMC6614043.

408 10. Kanga JM. Aspects épidémiologiques de l'ulcère de Buruli en Côte d'Ivoire : résultats d'une
409 enquête nationale. Bull Soc Pathol Exot. 2001;94:46-51.

410 11. Amofah G, Bonsu F, Tetteh C, Okrah J, Asamoa K, Asiedu K, et al. Buruli ulcer in Ghana:

411 results of a national case search. Emerging infectious diseases. 2002;8(2):167-70. Epub 2002/03/19.

412 doi: 10.3201/eid0802.010119. PubMed PMID: 11897068; PubMed Central PMCID: PMCPmc2732443.

413 12. Noeske J, Kuaban C, Rondini S, Sorlin P, Ciaffi L, Mbuagbaw J, et al. Buruli ulcer disease in

414 Cameroon rediscovered. The American journal of tropical medicine and hygiene. 2004;70(5):520-6.

415 Epub 2004/05/25. PubMed PMID: 15155984.

416 13. Garchitorena A, Roche B, Kamgang R, Ossomba J, Babonneau J, Landier J, et al.

417 Mycobacterium ulcerans ecological dynamics and its association with freshwater ecosystems and

418 aquatic communities: results from a 12-month environmental survey in Cameroon. PLoS neglected

419 tropical diseases. 2014;8(5):e2879. doi: 10.1371/journal.pntd.0002879. PubMed PMID: 24831924;

420 PubMed Central PMCID: PMCPMC4022459.

421 14. Williamson HR, Benbow ME, Nguyen KD, Beachboard DC, Kimbirauskas RK, McIntosh MD, et

422 al. Distribution of Mycobacterium ulcerans in buruli ulcer endemic and non-endemic aquatic sites in

423 Ghana. PLoS neglected tropical diseases. 2008;2(3):e205. Epub 2008/03/28. doi:

424 10.1371/journal.pntd.0000205. PubMed PMID: 18365034; PubMed Central PMCID:

425 PMCPmc2268743.

426 15. Campbell LP, Finley AO, Benbow ME, Gronseth J, Small P, Johnson RC, et al. Spatial Analysis

427 of Anthropogenic Landscape Disturbance and Buruli Ulcer Disease in Benin. PLoS neglected tropical

428 diseases. 2015;9(10):e0004123. Epub 2015/10/17. doi: 10.1371/journal.pntd.0004123. PubMed

429 PMID: 26474482; PubMed Central PMCID: PMCPmc4608567.

430 16. Wu UI, Holland SM. Host susceptibility to non-tuberculous mycobacterial infections. The

431 Lancet Infectious diseases. 2015;15(8):968-80. Epub 2015/06/08. doi: 10.1016/s1473-

432 3099(15)00089-4. PubMed PMID: 26049967.

433 17. Landier J, Gaudart J, Carolan K, Lo Seen D, Guegan JF, Eyangoh S, et al. Spatio-temporal
434 patterns and landscape-associated risk of Buruli ulcer in Akonolinga, Cameroon. PLoS neglected

435 tropical diseases. 2014;8(9):e3123. Epub 2014/09/05. doi: 10.1371/journal.pntd.0003123. PubMed
436 PMID: 25188464; PubMed Central PMCID: PMCPmc4154661.

437 18. Merritt RW, Walker ED, Small PL, Wallace JR, Johnson PD, Benbow ME, et al. Ecology and

438 transmission of Buruli ulcer disease: a systematic review. PLoS neglected tropical diseases.

439 2010;4(12):e911. Epub 2010/12/24. doi: 10.1371/journal.pntd.0000911. PubMed PMID: 21179505;

440 PubMed Central PMCID: PMCPmc3001905.

441 19. Portaels F, Meyers WM, Ablordey A, Castro AG, Chemlal K, de Rijk P, et al. First cultivation

442 and characterization of Mycobacterium ulcerans from the environment. PLoS neglected tropical

443 diseases. 2008;2(3):e178. Epub 2008/03/28. doi: 10.1371/journal.pntd.0000178. PubMed PMID:

444 18365032; PubMed Central PMCID: PMCPMC2268003.

445 20. Aboagye SY, Danso E, Ampah KA, Nakobu Z, Asare P, Otchere ID, et al. Isolation of

446 Nontuberculous Mycobacteria from the Environment of Ghanian Communities Where Buruli Ulcer Is

447 Endemic. Applied and environmental microbiology. 2016;82(14):4320-9. Epub 2016/05/22. doi:

448 10.1128/aem.01002-16. PubMed PMID: 27208141; PubMed Central PMCID: PMCPMC4959205.

449 21. Marsollier L, Aubry J, Milan G, Brodin P. Aquatic insects and transmission of Mycobacterium
450 ulcerans. M S-Med Sci. 2007;23(6-7):572-5. doi: 10.1051/medsci/20072367572. PubMed PMID:

451 WOS:000248183300005.

452 22. Willson SJ, Kaufman MG, Merritt RW, Williamson HR, Malakauskas DM, Benbow ME. Fish

and amphibians as potential reservoirs of Mycobacterium ulcerans, the causative agent of Buruli

454 ulcer disease. Infection ecology & epidemiology. 2013;3. Epub 2013/02/27. doi:

455 10.3402/iee.v3i0.19946. PubMed PMID: 23440849; PubMed Central PMCID: PMCPmc3580280.

456 23. Eric Benbow M, Kimbirauskas R, McIntosh MD, Williamson H, Quaye C, Boakye D, et al.

457 Aquatic macroinvertebrate assemblages of Ghana, West Africa: understanding the ecology of a

458 neglected tropical disease. EcoHealth. 2014;11(2):168-83. Epub 2013/12/07. doi: 10.1007/s10393-

459 013-0886-7. PubMed PMID: 24306551.

460 24. Carson C, Lavender CJ, Handasyde KA, O'Brien CR, Hewitt N, Johnson PD, et al. Potential

461 wildlife sentinels for monitoring the endemic spread of human buruli ulcer in South-East australia.

462 PLoS neglected tropical diseases. 2014;8(1):e2668. Epub 2014/02/06. doi:

463 10.1371/journal.pntd.0002668. PubMed PMID: 24498452; PubMed Central PMCID:

464 PMCPmc3907424.

465 25. McIntosh M, Williamson H, Benbow ME, Kimbirauskas R, Quaye C, Boakye D, et al.

466 Associations between Mycobacterium ulcerans and aquatic plant communities of West Africa:

467 implications for Buruli ulcer disease. EcoHealth. 2014;11(2):184-96. Epub 2014/01/21. doi:

468 10.1007/s10393-013-0898-3. PubMed PMID: 24442959.

469 26. Marion E, Chauty A, Yeramian E, Babonneau J, Kempf M, Marsollier L. A case of guilt by
470 association: Water bug bite incriminated in M. ulcerans infection. International journal of
471 mycobacteriology. 2014;3(2):158-61. Epub 2014/06/01. doi: 10.1016/j.ijmyco.2014.01.004. PubMed

472 PMID: 26786340.

473 27. Williamson HR, Benbow ME, Campbell LP, Johnson CR, Sopoh G, Barogui Y, et al. Detection

474 of Mycobacterium ulcerans in the environment predicts prevalence of Buruli ulcer in Benin. PLoS

475 neglected tropical diseases. 2012;6(1):e1506. Epub 2012/02/04. doi: 10.1371/journal.pntd.0001506.

476 PubMed PMID: 22303498; PubMed Central PMCID: PMCPmc3269429.

477 28. Johnson PDR. Buruli Ulcer in Australia. In: Pluschke G, Röltgen K, editors. Buruli Ulcer:

478 Mycobacterium Ulcerans Disease. Cham: Springer International Publishing; 2019. p. 61-76.

479 29. Wu J, Tschakert P, Klutse E, Ferring D, Ricciardi V, Hausermann H, et al. Buruli Ulcer Disease

480 and Its Association with Land Cover in Southwestern Ghana. PLoS neglected tropical diseases.

481 2015;9(6):e0003840. Epub 2015/06/20. doi: 10.1371/journal.pntd.0003840. PubMed PMID:

482 26091265; PubMed Central PMCID: PMCPmc4474842.

483 30. N'Krumah R T, Kone B, Tiembre I, Cisse G, Pluschke G, Tanner M, et al. Socio-Environmental

484 Factors Associated with the Risk of Contracting Buruli Ulcer in Tiassale, South Cote d'Ivoire: A Case-

485 Control Study. PLoS neglected tropical diseases. 2016;10(1):e0004327. Epub 2016/01/09. doi:

486 10.1371/journal.pntd.0004327. PubMed PMID: 26745723; PubMed Central PMCID:

487 PMCPmc4712845.

488 31. Marston B, Diallo MO, Horsburgh CR, Diomande I. Emergence of Buruli ulcer Disease in the
489 Daloa region of Côte d'Ivoire. The American journal of tropical medicine and hygiene. 1995;52:291490 24.

Raghunathan PL, Whitney EA, Asamoa K, Stienstra Y, Taylor TH, Jr., Amofah GK, et al. Risk
factors for Buruli ulcer disease (Mycobacterium ulcerans Infection): results from a case-control study
in Ghana. Clinical infectious diseases : an official publication of the Infectious Diseases Society of
America. 2005;40(10):1445-53. Epub 2005/04/22. doi: 10.1086/429623. PubMed PMID: 15844067.

495 33. Aiga H, Amano T, Cairncross S, Adomako J, Nanas OK, Coleman S. Assessing water-related

risk factors for Buruli ulcer: a case-control study in Ghana. The American journal of tropical medicine

497 and hygiene. 2004;71(4):387-92. Epub 2004/11/02. PubMed PMID: 15516631.

498 34. Simpson H, Deribe, K, Tabah, EN, Maman, I, Frimpong, M, Ampadu, E, Saunderson, P, Pullan,

499 RL and Cano, J. Occurrences of Buruli ulcer infections in humans and Mycobacterium ulcerans in

500 animal and environmental samples. 2018.

501 35. Fyfe JA, Lavender CJ, Johnson PD, Globan M, Sievers A, Azuolas J, et al. Development and

application of two multiplex real-time PCR assays for the detection of Mycobacterium ulcerans in

503 clinical and environmental samples. Applied and environmental microbiology. 2007;73(15):4733-40.

504 Epub 2007/05/29. doi: 10.1128/aem.02971-06. PubMed PMID: 17526786; PubMed Central PMCID:

505 PMCPMC1951036.

506 36. Lavender CJ, Stinear TP, Johnson PD, Azuolas J, Benbow ME, Wallace JR, et al. Evaluation of

507 VNTR typing for the identification of Mycobacterium ulcerans in environmental samples from

508 Victoria, Australia. FEMS microbiology letters. 2008;287(2):250-5. Epub 2008/08/30. doi:

509 10.1111/j.1574-6968.2008.01328.x. PubMed PMID: 18754785.

510 37. Stragier P, Ablordey A, Meyers WM, Portaels F. Genotyping Mycobacterium ulcerans and

511 Mycobacterium marinum by using mycobacterial interspersed repetitive units. J Bacteriol.

512 2005;187(5):1639-47. doi: 10.1128/jb.187.5.1639-1647.2005. PubMed PMID:

513 WOS:000227191600011.

514 38. Elith* J, H. Graham* C, P. Anderson R, Dudík M, Ferrier S, Guisan A, et al. Novel methods

improve prediction of species' distributions from occurrence data. Ecography. 2006;29(2):129-51.

516 39. Hijmans RJaE, J. Species distribution modeling with R. 2017.

517 40. Senay SD, Worner SP, Ikeda T. Novel three-step pseudo-absence selection technique for
518 improved species distribution modelling. PloS one. 2013;8(8):e71218.

519 41. Simpson H, Deribe K, Tabah EN, Peters A, Maman I, Frimpong M, et al. Mapping the global
520 distribution of Buruli ulcer: a systematic review with evidence consensus. The Lancet Global Health.
521 2019;7(7):e912-e22.

Barbet-Massin M, Jiguet F, Albert CH, Thuiller W. Selecting pseudo-absences for species
distribution models: how, where and how many? Methods in ecology and evolution. 2012;3(2):32738.

525 43. Stoffel V, Barthelme B, Chague F. [Tropical ecopathology: up hill and down dale Buruli ulcer].
526 Sante publique (Vandoeuvre-les-Nancy, France). 2005;17(2):191-7. Epub 2005/07/09. PubMed

527 PMID: 16001561.

528 44. Wilfried Thuiller DG, Robin Engler and Frank Breiner. biomod2: Ensemble Platform for

529 Species Distribution Modeling. R package version 3.3-15/r728. 2017.

530 45. Liu C, White M, Newell G. Measuring and comparing the accuracy of species distribution

531 models with presence-absence data. Ecography. 2011;34(2):232-43.

532 46. School of Geography and Environmental Science UoS. WorldPop Africa Continental

533 Population Datasets (2000- 2020). WorldPop 2018.

534 47. Yotsu RR, Suzuki K, Simmonds RE, Bedimo R, Ablordey A, Yeboah-Manu D, et al. Buruli Ulcer:

a Review of the Current Knowledge. Current Tropical Medicine Reports. 2018:1-10.

536 48. Roltgen K, Qi W, Ruf MT, Mensah-Quainoo E, Pidot SJ, Seemann T, et al. Single nucleotide

537 polymorphism typing of Mycobacterium ulcerans reveals focal transmission of buruli ulcer in a highly

endemic region of Ghana. PLoS neglected tropical diseases. 2010;4(7):e751. Epub 2010/07/24. doi:

539 10.1371/journal.pntd.0000751. PubMed PMID: 20652033; PubMed Central PMCID:

540 PMCPmc2907412.

541 49. III IdSC. Buruli ulcer in Equatorial Guinea [presentation]. In press 2006.

542 50. Ham A. AFIP Mycobacteriology Chief continues to attack Buruli ulcer in Third World
543 countries. the AFIP Letter. 2000;158(3):5.

544 51. Agbo I. The gendered impact of Buruli ulcer on the household production of health: why
545 decentralization favours women. Tropical Medicine & International Health. 2015;20:298-. PubMed
546 PMID: WOS:000360758801329.

547 52. Vincent QB, Ardant MF, Adeye A, Goundote A, Saint-Andre JP, Cottin J, et al. Clinical

epidemiology of laboratory-confirmed Buruli ulcer in Benin: a cohort study. The Lancet Global

549 health. 2014;2(7):e422-30. Epub 2014/09/05

550 2014/08/12. doi: 10.1371/journal.pntd.0003123

551 10.1016/s2214-109x(14)70223-2. PubMed PMID: 25103396.

- 552 53. Clements AC, Reid HL, Kelly GC, Hay SI. Further shrinking the malaria map: how can
- 553 geospatial science help to achieve malaria elimination? The Lancet Infectious Diseases.

554 2013;13(8):709-18. doi: 10.1016/S1473-3099(13)70140-3.

- 555 54. Deribe K, Beng AA, Cano J, Njouendo AJ, Fru-Cho J, Awah AR, et al. Mapping the
- 556 geographical distribution of podoconiosis in Cameroon using parasitological, serological, and clinical
- evidence to exclude other causes of lymphedema. PLoS neglected tropical diseases. 2018;12(1).
- 558 55. Wagner T, Benbow ME, Burns M, Johnson RC, Merritt RW, Qi J, et al. A Landscape-based
- 559 model for predicting Mycobacterium ulcerans infection (Buruli Ulcer disease) presence in Benin,
- 560 West Africa. EcoHealth. 2008;5(1):69-79. Epub 2008/07/24. doi: 10.1007/s10393-007-0148-7.
- 561 PubMed PMID: 18648799.
- 562
- 563







